AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30508863 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 16
Study 28202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan add-on therapy
Number of subjects: 50
Study 28202885 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretic therapy
Number of subjects: 50
Study 27550429 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely intraoperative iodine irrigation (0.33% povidone-iodine)
Number of subjects: 99
Study 27550429 — intervention group
Group type: COMPARATOR
Intervention: Control (no iodine irrigation)
Number of subjects: 99
Study 27550429 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely intraoperative iodine irrigation
Number of subjects: 99
Study 27550429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 27550429 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely iodine irrigation
Number of subjects: 99
Study 25186156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving calculated future fracture risk communicated to their GP with evidence-based recommendations.
Number of subjects: 0
Study 25186156 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care.
Number of subjects: 0
Study 22648554 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with or without SMT
Number of subjects: 291
Study 22648554 — intervention group
Group type: COMPARATOR
Intervention: SMT alone
Number of subjects: 291
Study 19519891 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss to follow-up (LTFU) participants had the event
Number of subjects: 0
Study 19519891 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the LTFU participants had the event
Number of subjects: 0
Study 19519891 — intervention group
Group type: EXPERIMENTAL
Intervention: All LTFU participants had the event
Number of subjects: 0
Study 19519891 — intervention group
Group type: EXPERIMENTAL
Intervention: All LTFU participants in the treatment group had the event; none in the control group (worst case scenario)
Number of subjects: 0
Study 19519891 — intervention group
Group type: EXPERIMENTAL
Intervention: Event incidence among LTFU participants increased in the intervention group
Number of subjects: 0
Study 19519891 — intervention group
Group type: COMPARATOR
Intervention: Event incidence among LTFU participants decreased in the control group
Number of subjects: 0
Study 17900783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-containing gum chewing
Number of subjects: 12
Study 17900783 — intervention group
Group type: COMPARATOR
Intervention: Chitosan mouth rinse solution
Number of subjects: 12
Study 15120509 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactide (PLA) barrier membranes during guided tissue regeneration (test)
Number of subjects: 10
Study 15120509 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap surgery (control)
Number of subjects: 10
Study 11786768 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 12
Study 11786768 — intervention group
Group type: COMPARATOR
Intervention: Straight group
Number of subjects: 12
Study 11786768 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch and Straight group
Number of subjects: 12
Study 10204813 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg controlled‐release nifedipine once daily
Number of subjects: 22
Study 10204813 — intervention group
Group type: COMPARATOR
Intervention: 20 mg sustained‐release nifedipine twice daily
Number of subjects: 22
Study 8646573 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow dye laser (580 nm)
Number of subjects: 210
Study 8646573 — intervention group
Group type: EXPERIMENTAL
Intervention: Red dye laser (630 nm)
Number of subjects: 210
Study 8646573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both yellow and red dye lasers
Number of subjects: 210
Study 8646573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye laser treatment
Number of subjects: 210
Study 2140929 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 100
Study 2140929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 366138 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 366138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30912681 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced instructor
Number of subjects: 74
Study 30912681 — intervention group
Group type: COMPARATOR
Intervention: Novice instructor
Number of subjects: 74
Study 27974169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics-first treatment (intravenous ertapenem for ≥48 hours, followed by oral cefdinir and metronidazole)
Number of subjects: 30
Study 27974169 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 30
Study 27974169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics-first treatment
Number of subjects: 30
Study 25881079 — intervention group
Group type: EXPERIMENTAL
Intervention: vandetanib
Number of subjects: 944
Study 25881079 — intervention group
Group type: COMPARATOR
Intervention: comparator
Number of subjects: 944
Study 24039797 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food supplements containing multiple vitamins and minerals provided daily for 1.5 years.
Number of subjects: 250
Study 21435103 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat infusion (F)
Number of subjects: 24
Study 21435103 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate infusion (C)
Number of subjects: 24
Study 21435103 — intervention group
Group type: COMPARATOR
Intervention: Protein infusion (P)
Number of subjects: 24
Study 19517420 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 31
Study 19517420 — intervention group
Group type: COMPARATOR
Intervention: Menses phase
Number of subjects: 31
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT outcome for heart attacks (NNT of 13 patients to prevent 1 heart attack)
Number of subjects: 2754
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: Large postponement for some patients (8 months for 1 of 4 patients)
Number of subjects: 2754
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: Short postponement for all patients (2 months)
Number of subjects: 2754
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT outcome for hip fractures (NNT of 57 patients to prevent 1 fracture)
Number of subjects: 2754
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: Large postponement for some patients (16 months for 3 of 100 patients)
Number of subjects: 2754
Study 17577004 — intervention group
Group type: EXPERIMENTAL
Intervention: Short postponement for all patients (16 days)
Number of subjects: 2754
Study 14762367 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (6-24 ng.kg(‐1).min(‐1))
Number of subjects: 32
Study 14762367 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients with normal platelet counts and no previous extended exposure to heparin)
Number of subjects: 32
Study 11182008 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic peak flow meter (actual data)
Number of subjects: 40
Study 11182008 — intervention group
Group type: COMPARATOR
Intervention: Written diary (reported data)
Number of subjects: 40
Study 11182008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (comparison of data)
Number of subjects: 40
Study 9517521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily for 12 weeks
Number of subjects: 70
Study 9517521 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 70
Study 9517521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70
Study 9517521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1333617 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (dose not specified)
Number of subjects: 0
Study 1333617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1333617 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 3901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid monopolar electrocoagulation
Number of subjects: 78
Study 3901730 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study 30107469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36)
Number of subjects: 46
Study 30107469 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 46
Study 28631347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 18
Study 26248590 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (CSII)
Number of subjects: 18
Study 24838896 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie Duo(®)
Number of subjects: 20
Study 24838896 — intervention group
Group type: COMPARATOR
Intervention: Low-speed bur
Number of subjects: 20
Study 23232168 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine Chloride (BC)
Number of subjects: 96
Study 23232168 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver (rehabilitation treatment)
Number of subjects: 96
Study 19318477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Number of subjects: 0
Study 18019593 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program
Number of subjects: 54
Study 15464318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on eight variables (hypotension, intra‐aortic balloon pump, congestive heart failure, chronic kidney disease, diabetes, age >75 years, anemia, and volume of contrast)
Number of subjects: 8357
Study 15464318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model applied in validation dataset
Number of subjects: 8357
Study 11256871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhormonal interventions for menopause symptoms
Number of subjects: 61
Study 9849693 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF starting on day +1
Number of subjects: 37
Study 9849693 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF starting on day +7
Number of subjects: 37
Study 7889637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg sustained release daily)
Number of subjects: 29
Study 7889637 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (240 mg sustained release daily)
Number of subjects: 29
Study 2924043 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural contracting
Number of subjects: 2
Study 2924043 — intervention group
Group type: EXPERIMENTAL
Intervention: Point systems
Number of subjects: 2
Study 2924043 — intervention group
Group type: EXPERIMENTAL
Intervention: Point systems plus response costs
Number of subjects: 2
Study 209485 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg estradiol valerate (single oral dose)
Number of subjects: 0
Study 209485 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosages of estrogens
Number of subjects: 0
Study 29642743 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly problem‐based sessions led by psychologists over 3 months
Number of subjects: 166
Study 29642743 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention led by psychologists over 9 months
Number of subjects: 166
Study 29642743 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study 31188153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted paramedian spinal anaesthesia
Number of subjects: 80
Study 31188153 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided paramedian spinal anaesthesia
Number of subjects: 80
Study 26625194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy (early surgical haemostasis, mechanical pressure on uterine wall, intrauterine balloon tamponade)
Number of subjects: 119
Study 26625194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy
Number of subjects: 119
Study 26163031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous anaesthesia delivered by the computerised QuickSleeper system
Number of subjects: 160
Study 26163031 — intervention group
Group type: COMPARATOR
Intervention: Conventional infiltration anaesthesia
Number of subjects: 160
Study 24115188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day)
Number of subjects: 68
Study 24115188 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 68
Study 21817061 — intervention group
Group type: EXPERIMENTAL
Intervention: EGJ distension
Number of subjects: 10
Study 21817061 — intervention group
Group type: COMPARATOR
Intervention: No EGJ distension (control)
Number of subjects: 10
Study 22253983 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 14
Study 22253983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17115389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 15518603 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction (TIMI) risk score (TRS)
Number of subjects: 3801
Study 10955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy focusing on reversing the underlying disorder and providing supportive treatment
Number of subjects: 0
Study 10955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific tests
Number of subjects: 0
Study 9244023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 75
Study 9244023 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 325 mg/dextropropoxyphene hydrochloride 32.5 mg
Number of subjects: 75
Study 9244023 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg/codeine phosphate 30 mg
Number of subjects: 75
Study 8143995 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with folinic acid 200 mg/m2 plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles
Number of subjects: 239
Study 8143995 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 239
Study 3260554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media (sodium meglumine and amidotrizoate)
Number of subjects: 46
Study 3260554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iohexol)
Number of subjects: 46
Study 31216210 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference psychotherapy (VC)
Number of subjects: 207
Study 31216210 — intervention group
Group type: COMPARATOR
Intervention: In-person psychotherapy (IP)
Number of subjects: 207
Study 31279324 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 78
Study 31279324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 29231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 90
Study 29231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 29231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medication (carbamazepine)
Number of subjects: 90
Study 25447041 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous external chest compressions plus continuous oxygen insufflation (C‐CPR)
Number of subjects: 7
Study 25447041 — intervention group
Group type: COMPARATOR
Intervention: Standard‐CPR (S‐CPR)
Number of subjects: 7
Study 25447041 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐CPR
Number of subjects: 7
Study 23134408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with 6 months steroids withdrawal (6M SW)
Number of subjects: 502
Study 23134408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with 3 months steroids withdrawal (3M SW)
Number of subjects: 502
Study 23134408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with 14 days steroids withdrawal (14d SW)
Number of subjects: 502
Study 23134408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with basiliximab induction and steroids avoidance (Bas SA)
Number of subjects: 502
Study 23134408 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 502
Study 21536090 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 polymorphisms (-174G/C, -572G/C)
Number of subjects: 30
Study 21536090 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses by ethnicity and quality score
Number of subjects: 30
Study 21536090 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-regression analysis
Number of subjects: 30
Study 21536090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion of the meta-analysis
Number of subjects: 30
Study 19499294 — intervention group
Group type: EXPERIMENTAL
Intervention: C4‐6 laminoplasty preserving the C7 spinous process and its attached muscles (group A)
Number of subjects: 43
Study 19499294 — intervention group
Group type: COMPARATOR
Intervention: C4‐7 laminoplasty (group B)
Number of subjects: 43
Study 16616449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomp Out Smokes (SOS)
Number of subjects: 139
Study 16616449 — intervention group
Group type: COMPARATOR
Intervention: Brief Office Intervention (BOI)
Number of subjects: 139
Study 15199653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and psychoeducation
Number of subjects: 52
Study 15199653 — intervention group
Group type: COMPARATOR
Intervention: Medication without psychoeducation
Number of subjects: 52
Study 11300428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 11
Study 11300428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 11
Study 11300428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11300428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 400 microg sublingual
Number of subjects: 11
Study 9378379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 micrograms/kg intravenous bolus and 4 micrograms/kg/h maintenance dose)
Number of subjects: 10
Study 9378379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10
Study 7506179 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 99
Study 7506179 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 99
Study 3535012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 8 mg intravenously
Number of subjects: 0
Study 3535012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg intravenously
Number of subjects: 0
Study 3535012 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 1 mg atropine pretreatment
Number of subjects: 0
Study 3535012 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol 250 micrograms subcutaneously
Number of subjects: 0
Study 3535012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily (1-week treatment)
Number of subjects: 0
Study 28921241 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 6.5 mg
Number of subjects: 464
Study 28921241 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 3.25 mg
Number of subjects: 464
Study 28921241 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 6.25 mg
Number of subjects: 464
Study 28921241 — intervention group
Group type: COMPARATOR
Intervention: Plain moisturizer (PM)
Number of subjects: 464
Study 26046585 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml of water
Number of subjects: 17
Study 26046585 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 17
Study 25013997 — intervention group
Group type: COMPARATOR
Intervention: NNC0195‐0092 (0.01‐0.32 mg/kg) single dose
Number of subjects: 105
Study 25013997 — intervention group
Group type: COMPARATOR
Intervention: NNC0195‐0092 (0.02‐0.24 mg/kg) once-weekly doses for 4 weeks
Number of subjects: 105
Study 25013997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 23975746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer-HCl
Number of subjects: 40
Study 23975746 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 40
Study 23975746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phosphate binders
Number of subjects: 40
Study 22052374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance (BIA)
Number of subjects: 40
Study 22052374 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium Dilution Method (DDM)
Number of subjects: 40
Study 18474811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (150 mg s.c.)
Number of subjects: 23
Study 18474811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 23
Study 18474811 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 23
Study 17176380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 41
Study 17176380 — intervention group
Group type: COMPARATOR
Intervention: School Counseling (SC)
Number of subjects: 41
Study 14600860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 30
Study 14600860 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with sufentanil 0.5 microg/ml
Number of subjects: 30
Study 11124070 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 40
Study 11124070 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-of-flight MR angiography
Number of subjects: 40
Study 11124070 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 40
Study 11124070 — intervention group
Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 40
Study 8869862 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (group 1: 0.3 mg.kg‐1 i.v. bolus, 0.12 mg.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61
Study 8869862 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (group 2: 0.5 mg.kg‐1 i.v. bolus, 0.24 mg.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61
Study 8869862 — intervention group
Group type: COMPARATOR
Intervention: Heparin (150 IU.kg‐1 i.v. bolus, 20 IU.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61